Strategic Industry Coalition Debuts Amid Calls for National Biomanufacturing Strategy
May 21, 2025 — Washington, D.C. — A consortium of leading biotech and industrial firms has launched the American Alliance for Biomanufacturing (AAB), a groundbreaking coalition aimed at bolstering U.S. leadership in biomanufacturing. This move responds directly to the National Security Commission on Emerging Biotechnology (NSCEB) recommendations urging a whole-of-government approach to secure America’s competitiveness in this critical sector.
Founding Members and Strategic Goals
Founding members include industry heavyweights such as Manus Bio, Pivot Bio, Novonesis, Kula Bio, IFF Health & Biosciences, Lallemand Biofuels & Distilled Spirits, LanzaTech Global, Liberation Labs, Synonym, POET, Ferment Co, and Geno. Together, they aim to:
- Accelerate domestic demand for bio-based products and technologies.
- Ensure market readiness for innovative and existing bioproducts.
- Reinforce U.S.-based supply chains for biological materials and equipment.
“Biomanufacturing is a strategic imperative,” said Ajikumar “Aji” Parayil, CEO of Manus Bio. “The Alliance is a focused step toward a national strategy that links innovation with economic growth, job creation, and sustainability.”
National Security and Economic Resilience
The formation of AAB aligns with findings in the NSCEB’s final report, which stresses the strategic importance of biomanufacturing to U.S. national security. The report advocates for substantial federal investments and the creation of a National Biotechnology Coordination Office to unify agency efforts.
“Without prompt action, the U.S. risks falling behind nations like China that have already made biotechnology a priority,” noted the NSCEB.
Economic and Environmental Impacts
The global biomanufacturing industry, currently valued at $20 billion, is poised for rapid growth. By integrating biological systems to produce energy, chemicals, agricultural inputs, and consumer goods, the AAB seeks to:
- Drive job creation, particularly in rural and underserved areas.
- Enhance U.S. resilience by reducing reliance on global supply chains.
- Promote sustainable practices across multiple sectors.
“Our goal is to bring U.S.-invented biotech home,” said Mark Warner, CEO of Liberation Labs. “With AAB leadership, we can build next-generation facilities on American soil.”
Export Perspectives and Global Outlook
As the Alliance expands, focus will include scaling up export capabilities for bio-based materials. The U.S. currently exports significant quantities of biofuels and bio-based chemicals, primarily to Canada, the EU, and Japan. Key exporters include POET and LanzaTech, which are poised to benefit from improved infrastructure and strategic alignment.
Looking Ahead
Brooke Coleman, Executive Director of AAB, concluded: “We are laying the foundation for the 21st-century bioeconomy. By acting together and recognizing global market realities, the U.S. can lead the future of industrial biomanufacturing.”
